IMBiologics Corp.
The provided URL returned a 404 Page Not Found and displayed a hosting provider error page. No company-specific information, capabilities, products, leadership, or contact details for the company were available on the supplied page.
Industries
Nr. of Employees
small (1-50)
IMBiologics Corp.
Seongnam, Kyonggi-do, South Korea, Asia
Products
IMB-101 (NAV-240)
A bispecific antibody targeting OX40L and TNFα designed to modulate immune responses in autoimmune and inflammatory diseases.
IMB-102 (NAV-140)
A monoclonal antibody targeting OX40L to inhibit immune cell activation in autoimmune diseases.
IMB-201 and IMB-202
Antibody drug candidates under development targeting immune modulation for autoimmune and inflammatory diseases.
IMB-401 and IMB-402
Antibody drug candidates focused on immune modulation for treatment of autoimmune diseases.
IM-OpDECon Technology
A proprietary antibody discovery platform technology used to develop immunomodulatory antibody drugs.
ePENDY Technology
A platform technology employed in the development of antibody therapeutics with immunomodulatory properties.
IMB-101 (NAV-240)
A bispecific antibody targeting OX40L and TNFα designed to modulate immune responses in autoimmune and inflammatory diseases.
IMB-102 (NAV-140)
A monoclonal antibody targeting OX40L to inhibit immune cell activation in autoimmune diseases.
IMB-201 and IMB-202
Antibody drug candidates under development targeting immune modulation for autoimmune and inflammatory diseases.
IMB-401 and IMB-402
Antibody drug candidates focused on immune modulation for treatment of autoimmune diseases.
IM-OpDECon Technology
A proprietary antibody discovery platform technology used to develop immunomodulatory antibody drugs.
ePENDY Technology
A platform technology employed in the development of antibody therapeutics with immunomodulatory properties.